Transmucosal Immediate-Release Fentanyl (TIRF) Medicines

Transmucosal immediate-release fentanyl (TIRF) medicines contain fentanyl, a powerful prescription opioid pain reliever. TIRF medicines include Abstral (fentanyl) sublingual tablet, Actiq (fentanyl citrate) oral transmucosal lozenge, Fentora (fentanyl citrate) buccal tablet, Lazanda (fentanyl) nasal spray, Onsolis (fentanyl) buccal soluble film, Subsys (fentanyl) sublingual spray, and approved generic equivalents of Actiq, Abstral, and Fentora.

The TIRF medicines are indicated for the management of breakthrough pain in cancer patients 18 years of age and older (16 years of age and older for Actiq and its generic equivalents) who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.

Breakthrough pain comes on suddenly for short periods of time and is not alleviated by a patient’s normal pain management plan. To use the TIRF medicines safely, these patients must be opioid tolerant based on concurrent regular use of another opioid medication.

Contact FDA

1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 03/27/2019
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English